贝达喹啉和德拉马尼治疗耐多药结核病对心电图QT间期影响的研究进展  

Effect of Bedaquiline and Delamanid on QT interval of electrocardiogram in the treatment for multidrug-resistant tuberculosis

作　　者：孙玙贤 舒薇[1] 刘宇红[1] Sun Yuxian;Shu Wei;Liu Yuhong(Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute/Clinical Center on Tuberculosis,China CDC,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京胸科医院、北京市结核病胸部肿瘤研究所、中国疾病预防控制中心结核病防治临床中心,北京101149

出　　处：《中华结核和呼吸杂志》2023年第3期290-294,共5页Chinese Journal of Tuberculosis and Respiratory Diseases

基　　金：首都医科大学附属北京胸科医院种子计划。

摘　　要：耐多药结核病的治疗面临诸多挑战, 抗结核药物贝达喹啉和德拉马尼作为近50年出现的具有新作用机制的药物, 为耐多药结核病患者治疗提供了新的选择。相关研究表明, 这两种药物可导致心电图QT间期延长。本文旨在通过对两种抗结核新药对于QT间期延长机制、单药应用和多药联用下的适应证、禁忌证及注意事项进行综述, 以期为临床使用贝达喹啉和德拉马尼治疗耐多药结核病提供参考。Treatment for multidrug-resistant tuberculosis(MDR-TB)is extremely difficult.In the recent 50 years,bedaquiline and delamanid have emerged as novel anti-tuberculosis drugs with new action mechanisms,providing additional options for MDR-TB treatment.Relevant studies had shown that these two drugs might prolong the QT interval on electrocardiogram.In this review,the mechanism of prolonging QT interval by these two new anti-tuberculosis drugs,the indications,the contraindications and the precautions under single drug application or multi-drug combination were summarized to provide references for the clinical use of bedaquiline and delamanid in the treatment of MDR-TB.

关 键 词：耐多药结核病 抗结核新药 QT间期延长 抗结核药物 禁忌证 贝达喹啉 新作用机制 患者治疗 

分 类 号：R52[医药卫生—内科学]